Exosome Diagnostics is a technology company.
Exosome Diagnostics has raised $111.0M across 5 funding rounds.
Exosome Diagnostics has raised $111.0M in total across 5 funding rounds.
Exosome Diagnostics has raised $111.0M in total across 5 funding rounds.
Exosome Diagnostics's investors include Arcus Ventures, Forbion.
Exosome Diagnostics is a diagnostics company specializing in non-invasive, exosome-based liquid biopsy tests for cancer detection and monitoring, primarily targeting prostate cancer. Its flagship product, the ExoDx Prostate (IntelliScore or EPI), is a urine-based test that predicts high-grade prostate cancer risk, helping patients and physicians avoid unnecessary biopsies; it serves urologists, oncologists, and patients while addressing the problem of overdiagnosis in prostate cancer screening.[1][2][4][5] The company also provides biopharma services for biomarker discovery using exosomal RNA, cell-free DNA, and proteins, and has pursued companion diagnostics (CDx) collaborations with pharmaceutical firms; it was acquired by Bio-Techne in 2018 but divested to Mdxhealth in August 2025, retaining its CLIA-certified labs in the US and Europe for continued growth in urology diagnostics.[2][4]
Exosome Diagnostics emerged from pioneering research on exosomes—microvesicles released by cells into biofluids like urine and blood, carrying intact nucleic acids and proteins for molecular analysis. The company commercialized its proprietary Exo-Lution™ platform for minimally invasive diagnostics in personalized medicine, with early focus on cancer markers; its European arm in Martinsried, Germany, handles ISO 13485-certified IVD products.[1][2] Key figures include Mikkel Noerholm, PhD, MBA, as Head of European Operations; it gained traction with the ExoDx Prostate test, the world's first exosome-based clinical diagnostic, now included in 2019 NCCN Guidelines and soon as CE-IVD in Europe.[2] Investor Forbion backed it as a "realised" portfolio company, reflecting successful commercialization before Bio-Techne's 2018 acquisition and the 2025 divestiture to Mdxhealth.[1][4]
Exosome Diagnostics rides the liquid biopsy wave in precision oncology, shifting from invasive tissue biopsies to biofluid analysis amid rising demand for personalized medicine and early cancer detection. Timing aligns with NCCN guideline adoption and regulatory progress (e.g., CE-IVD), fueled by market forces like prostate cancer prevalence and biopsy avoidance to cut healthcare costs.[2][4] It influences the ecosystem by pioneering exosome tech—validating extracellular vesicles for diagnostics—and enabling pharma CDx, now amplified by Mdxhealth's urology portfolio for broader clinician adoption.[1][2][4]
Under Mdxhealth, Exosome Diagnostics will likely expand ExoDx Prostate adoption in urology, integrating with genetic/epigenetic tests for comprehensive cancer risk profiling. Trends like AI-enhanced biomarker analysis and exosome drug delivery could extend its platform beyond diagnostics. Its influence may grow by standardizing non-invasive monitoring, reducing overtreatment, and partnering deeper in oncology—building on its trailblazing liquid biopsy foundation to shape accessible precision medicine.[4]
Exosome Diagnostics has raised $111.0M across 5 funding rounds. Most recently, it raised $30.0M Series C in July 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2017 | $30.0M Series C | Arcus Ventures, Forbion | |
| Jan 1, 2016 | $16.0M Series B | Arcus Ventures, Forbion | |
| Sep 1, 2015 | $18.0M Series B | Arcus Ventures, Forbion | |
| Mar 1, 2014 | $27.0M Series B | Arcus Ventures, Forbion | |
| May 1, 2010 | $20.0M Series A | Forbion |